163 related articles for article (PubMed ID: 33848589)
1. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
[TBL] [Abstract][Full Text] [Related]
2. Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IM; Punt A
Arch Toxicol; 2013 Sep; 87(9):1709-23. PubMed ID: 23943240
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
5. Application of physiologically based kinetic (PBK) modelling in the next generation risk assessment of dermally applied consumer products.
Moxon TE; Li H; Lee MY; Piechota P; Nicol B; Pickles J; Pendlington R; Sorrell I; Baltazar MT
Toxicol In Vitro; 2020 Mar; 63():104746. PubMed ID: 31837441
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
7. Next generation risk assessment for occupational chemical safety - A real world example with sodium-2-hydroxyethane sulfonate.
Wood A; Breffa C; Chaine C; Cubberley R; Dent M; Eichhorn J; Fayyaz S; Grimm FA; Houghton J; Kiwamoto R; Kukic P; Lee M; Malcomber S; Martin S; Nicol B; Reynolds J; Riley G; Scott S; Smith C; Westmoreland C; Wieland W; Williams M; Wolton K; Zellmann T; Gutsell S
Toxicology; 2024 Jun; 506():153835. PubMed ID: 38857863
[TBL] [Abstract][Full Text] [Related]
8. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
9. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
10. The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine.
Bessems JGM; Paini A; Gajewska M; Worth A
Toxicology; 2017 Dec; 392():119-129. PubMed ID: 28288858
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
Kullenberg F; Degerstedt O; Calitz C; Pavlović N; Balgoma D; Gråsjö J; Sjögren E; Hedeland M; Heindryckx F; Lennernäs H
Cells; 2021 Jul; 10(7):. PubMed ID: 34359887
[TBL] [Abstract][Full Text] [Related]
13. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
[TBL] [Abstract][Full Text] [Related]
14. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin.
Assumpção JU; Campos ML; Ferraz Nogueira Filho MA; Pestana KC; Baldan HM; Formariz Pilon TP; de Oliveira AG; Peccinini RG
J Pharm Sci; 2013 Jan; 102(1):289-96. PubMed ID: 23150468
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
[TBL] [Abstract][Full Text] [Related]
17. Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment.
Reale E; Zare Jeddi M; Paini A; Connolly A; Duca R; Cubadda F; Benfenati E; Bessems J; S Galea K; Dirven H; Santonen T; M Koch H; Jones K; Sams C; Viegas S; Kyriaki M; Campisi L; David A; Antignac JP; B Hopf N
Environ Int; 2024 Feb; 184():108474. PubMed ID: 38350256
[TBL] [Abstract][Full Text] [Related]
18. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
20. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
